Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Aurora kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aurora Kinase (75) Adenosine Receptor (1) Akt (2) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (17) Autophagy (8) Bcr-Abl (7) c-Fms (1) c-Kit (1) c-Myc (1) CaMK (1) CDK (3) EGFR (1) Endogenous Metabolite (1) FAK (1) FGFR (3) FLT3 (8) G Protein-coupled Receptor Kinase (GRK) (1) GSK-3 (1) Histone Methyltransferase (1) IGF-1R (1) JAK (5) LIM Kinase (LIMK) (1) LRRK2 (1) MEK (1) Microtubule/Tubulin (1) NEKs (2) p38 MAPK (1) PARP (1) PDGFR (3) PERK (1) PKC (1) Polo-like Kinase (PLK) (1) PROTACs (4) Reactive Oxygen Species (1) ROCK (1) Src (4) STAT (4) Syk (1) TAM Receptor (1) Tie (1) VEGFR (5)
By Research Areas:	Cancer (77) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (3) Neurological Disease (1)
Click Chemistry:	Alkynes (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Click Chemistry

Targets Recommended: Aurora Kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151971

Aurora Kinases-IN-3	Aurora Kinase Polo-like Kinase (PLK)	Cancer
Aurora Kinases-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10 .

HY-112273

CD532	Aurora Kinase	Cancer
CD532 is a potent **Aurora A kinase inhibitor with an IC₅₀** of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer .

HY-150592

Aurora Kinases-IN-2	Aurora Kinase	Cancer
Aurora Kinases-IN-2 (compound 12Aj) is a potent **Aurora kinases inhibitor with IC₅₀** values of 90 and 152 nM for Aurora A and Aurora B. Aurora Kinases-IN-2 arrests cell cycle at G2/M phase by regulating cyclin B1 and cdc2. Aurora Kinases-IN-2 can be used for cancer research .

HY-149354

Aurora Kinases-IN-4	Aurora Kinase	Cancer
Aurora Kinases-IN-4 (Compound 11c) is a covalent and ATP competitive aurora kinase A inhibitor (IC₅₀: 1.7 nM). Aurora Kinases-IN-4 inhibits cell proliferation in SJSA-1, MDA-MB-231, A54, HeLa cells with IC₅₀s of 4.27, 1.54, 3.08, 6.99 μM. Aurora Kinases-IN-4 can be used for research of triple negative breast cancer (TNBC) .

HY-122370A

Tripolin B	Aurora Kinase	Cancer
Tripolin B is an ATP-competitive **Aurora kinase inhibitor with IC₅₀** values of 2.5 µM and 6 µM for Aurora A and Aurora B kinases, respectively. Tripolin B does not inhibit Aurora kinase in cells .

HY-149693

Aurora kinase inhibitor-11	Aurora Kinase	Cancer
Aurora kinase inhibitor-11 (compound 25) is an inhibitor of Aurora Kinase with an IC₅₀ of 0.14 μM. Aurora kinase inhibitor-11 has anticancer activity .

HY-160447

*FAK/aurora* kinase-IN-1**	Aurora Kinase FAK	Cancer
FAK/aurora kinase-IN-1 is a FAK and **aurora kinase inhibitor with IC₅₀** values of 6.61 nM and 0.91 nM, respectively. FAK/aurora kinase-IN-1 shows anticancer effects (WO2018019252A1; compound 11) .

HY-149694

Aurora kinase inhibitor-12	Aurora Kinase	Cancer
Aurora Kinase Inhibitor-12 (Compound 1a ) is the inhibitor of **aurora kinase** which is a key enzyme that is implicated in tumor growth .

HY-144438

Aurora/LIM kinase-IN-1	Aurora Kinase LIM Kinase (LIMK)	Cancer
Aurora/LIM kinase-IN-1 (Compound F114) is a potent and dual inhibitor of *aurora* and lim kinase. Aurora kinases and lim kinases are involved in neoplastic cell division and cell motility, respectively. Aurora/LIM kinase-IN-1 inhibits GBM proliferation and invasion. Aurora/LIM kinase-IN-1 is a promising new scaffold for dual aurora/lim kinase inhibitors that may be used in future agent development efforts for GBM, and potentially other cancers .

HY-115932

Aurora kinase-IN-1	Aurora Kinase Apoptosis	Cancer
Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of **aurora kinase*. Aurora* kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents .

HY-112273A

CD532 hydrochloride	Aurora Kinase	Cancer
CD532 hydrochloride is a potent **Aurora A kinase inhibitor with an IC₅₀** of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer .

HY-129727

(E)-MS0019266	Others	Others
(E)-MS0019266 is a potent inhibitor of DNA damage repair. (E)-MS0019266 inhibits ribonucleotide reductase by generating reactive oxygen species. (E)-MS0019266 also reduces expression of genes related to cell cycle arrest and mitosis, including polo-like kinase 1, kinesin family member 20a, cyclin B1 and aurora kinase A. (E)-MS0019266 is promising for research of inhibitors of ribonucleotide reductase and polo-like kinase 1 .

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, **Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀**=55 nM) .

HY-112355

Aurora kinase inhibitor-2	Aurora Kinase	Cancer
Aurora kinase inhibitor-2 is a selective and ATP-competitive **Aurora kinase inhibitor with IC₅₀*s of 310 nM and 240 nM for Aurora* A and Aurora B, respectively .

HY-144991

Aurora kinase inhibitor-8	Aurora Kinase	Cancer
Aurora kinase inhibitor-8 is a highly selective inhibitor of the **Aurora kinases**.

HY-147703

Aurora kinase inhibitor-9	Aurora Kinase	Cancer
Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B dual aurora kinase inhibitor with IC₅₀s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity .

HY-111506

Aurora inhibitor 1	Aurora Kinase	Cancer
Aurora inhibitor 1 is a potent *Aurora* inhibitor with an IC₅₀ of ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase, respectively .

HY-147993

Aurora kinase inhibitor-10	Aurora Kinase	Cancer
Aurora kinase inhibitor-10 (Compound 6c) is an orally active Aurora B inhibitor with an IC₅₀ of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity .

HY-14711

Reversine 5+ Cited Publications	Aurora Kinase Autophagy	Cancer
Reversine is a novel class of ATP-competitive **Aurora kinase inhibitor with IC₅₀*s of 400, 500 and 400 nM for Aurora* A, Aurora B and Aurora C, respectively.

HY-112373

Aurora kinase inhibitor-3	Aurora Kinase	Others
Aurora kinase inhibitor-3 is a strong and selective **Aurora A kinase inhibitor with an IC₅₀** of 42 nM, and weakly inhibits EGFR with an IC₅₀ of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket .

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual FLT3 and **Aurora kinase** inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-123610

BRD-7880	Aurora Kinase	Cancer
BRD-7880 is a potent and highly specific inhibitor of Aurora Kinase B (AURKB) and Aurora Kinase C (AURKC), with IC₅₀ values of 7 nM and 12 nM, respectively .

HY-10128

ZM-447439 5+ Cited Publications	Aurora Kinase Apoptosis	Cancer
ZM-447439 is an *aurora* kinase inhibitor with IC₅₀s of 110 and 130 nM for aurora A and B, respectively.

HY-10179

Danusertib 5+ Cited Publications PHA-739358	Aurora Kinase Autophagy	Cancer
Danusertib is a pyrrolo-pyrazole and **aurora kinase inhibitor with IC₅₀** of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

HY-124330

Tripolin A (E)-Tripolin A	Aurora Kinase	Others
Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive **Aurora A kinase inhibitor, with IC₅₀** values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively .

HY-12049

CCT129202	Aurora Kinase	Cancer
CCT129202 is an *aurora* kinase inhibitor with IC₅₀s of 42, 198, and 227 nM for aurora A, B and C, respectively.

HY-141512

JB170 1 Publications Verification	PROTACs Aurora Kinase	Cancer
JB170 is a potent and highly specific PROTAC-mediated *AURORA-A* (Aurora *Kinase) degrader (DC₅₀=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC₅₀=193 nM) over AURORA-B (EC₅₀=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase* .

HY-10178

PHA-680632	Aurora Kinase	Cancer
PHA-680632 is an *aurora* kinase inhibitor with IC₅₀s of 27, 135 and 120 nM for aurora A, B and C, respectively.

HY-N3737

Derrone	Aurora Kinase PERK Reactive Oxygen Species	Cancer
Derrone, a prenylated isoflavones, is an **Aurora kinase inhibitor, with IC₅₀** values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity .

HY-13253

AMG 900 3 Publications Verification	Aurora Kinase	Cancer
AMG 900 is a potent and highly selective *pan-Aurora* kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.

HY-146037

Aurora A inhibitor 2	Apoptosis Aurora Kinase	Cancer
Aurora A inhibitor 2 (Compound 16h) is a potent **Aurora A kinase inhibitor with an IC₅₀** of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent apoptosis in MDA-MB-231 cells .

HY-10804

CCT 137690 1 Publications Verification	Aurora Kinase Apoptosis	Cancer
CCT 137690 is a potent and orally available *aurora* kinase inhibitor with IC₅₀s of 15, 25, and 19 nM for aurora A, B and C, respectively.

HY-103266

TC-A 2317 hydrochloride	Aurora Kinase	Cancer
TC-A 2317 hydrochloride is an orally active **Aurora A kinase inhibitor (K_i*=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora* B kinase (K_i=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity .

HY-121998

Binucleine 2	Aurora Kinase	Others
Binucleine 2 is an isoform-specific and ATP-competitive inhibitor of Drosophila Aurora B kinase (Ki=0.36 μM), a kinase involved in cell division. It is specific for Drosophila Aurora B kinase, inhibiting it in a dose-dependent manner, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 μM. Binucleine 2 induces mitotic and cytokinesis defects in Drosophila Kc167 cells. It prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 μM but does not affect ring ingression, suggesting that Aurora B kinase activity is not required for that step.

HY-12003

SNS-314 mesylate 2 Publications Verification	Aurora Kinase	Cancer
SNS-314 mesylate is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-108344

SNS-314	Aurora Kinase	Cancer
SNS-314 is a potent and selective *aurora* kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively .

HY-123279

OM137	Aurora Kinase CDK	Cancer
OM137 is an **aurora kinase** inhibitor, with an IC₅₀ of 21.7 μM (Aurora A kinase) and 2.4 μM (Aurora B kinase). OM137 also inhibits Cdk1/cyclinB and Cdk5/p25 with an approximate IC₅₀ of 20 μM. OM137 reduces spindle checkpoint-signaling proteins (Mad2 and BubR1) at the kinetochores of chromosomes .

HY-13819

MK-8745 4 Publications Verification	Aurora Kinase Apoptosis	Cancer
MK-8745 is an aurora A kinase inhibitor with an IC₅₀ of 0.6 nM.

HY-10329

JNJ-7706621 2 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent **aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B**, respectively .

HY-10057

AT9283 hydrochloride	Aurora Kinase	Cancer
AT9283 hydrochloride is a multi-targeted kinase inhibitor with anti-tumor activity. AT9283 hydrochloride has been found to effectively inhibit Aurora A and Aurora B kinases, thereby affecting cell proliferation and survival. AT9283 hydrochloride can also inhibit several other kinases, including JAK2 and Abl (T315I) .

HY-10180

MLN8054 5+ Cited Publications	Aurora Kinase	Cancer
MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC₅₀ of 4 nM.

HY-121895

BI 831266	Aurora Kinase	Cancer
BI 831266 is a potent and selective inhibitor of Aurora kinase B with antitumor activity .

HY-137377

TAS-119	Aurora Kinase	Cancer
TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC₅₀ of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC₅₀ of 95 nM). TAS-119 has potent antitumor activites .

HY-156378

Aurora A inhibitor 3	Aurora Kinase	Cancer
Aurora A inhibitor 3 (Compound 5h) inhibits Aurora-A kinase with an IC₅₀ value of 0.78 μM. Aurora A inhibitor 3 is cytotoxic, with GI₅₀ values of 0.12 μM and 0.63 μM for MCF-7 and MDA-MB-231 cells, respectively .

HY-13252

MK-5108 4 Publications Verification VX-689	Aurora Kinase Autophagy	Cancer
MK-5108 is a highly potent and specific inhibitor of **Aurora A kinase with an IC₅₀** value of 0.064 nM.

HY-113894

Retreversine	Aurora Kinase	Cancer
Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor .

HY-145601

Tinengotinib TT 00420	Aurora Kinase VEGFR	Cancer
Tinengotinib is the modulator of one or more protein kinases such as *Aurora* kinase and VEGFR kinase. Tinengotinib has the potential for the research of these kinase abnormalities diseases mediated, especially cancer-related diseases (extracted from patent WO2018108079A1) .

HY-10971A

Alisertib sodium MLN 8237 sodium	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) sodium is an orally active and selective **Aurora A kinase inhibitor (IC₅₀*=1.2 nM), which binds to Aurora* A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-10971

Alisertib Maximum Cited Publications 49 Publications Verification MLN 8237	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) is an orally active and selective **Aurora A kinase inhibitor (IC₅₀*=1.2 nM), which binds to Aurora* A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-10339

KW-2449 5+ Cited Publications	FLT3 FGFR Bcr-Abl Aurora Kinase Apoptosis	Cancer
KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABL ^T315I and **Aurora kinase with IC₅₀**s of 6.6, 14, 4 and 48 nM, respectively.

Cat. No.	Product Name

HY-L004

Cell Cycle/DNA Damage Compound Library

2,345 compounds

DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.

MCE owns a unique collection of 2,345 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cat. No.	Product Name		Classification

HY-116423

JH295		Alkynes
JH295 is a potent, irreversible and selective *NIMA-related kinase* 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2** via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-116423A

JH295 hydrate		Alkynes
JH295 hydrate is a potent, irreversible and selective *NIMA-related kinase* 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular Nek2** via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks